Measles Seroprevalence and Vaccine Responses in Human Immunodeficiency Virus–infected Adolescents and Adults: A Systematic Review
- 17 November 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 69 (5) , 836-844
Abstract
Background: The World Health Organization (WHO) recommends an additional dose of measles-containing vaccine (MCV) for human immunodeficiency virus (HIV)–infected children receiving highly active antiretroviral therapy following immune reconstitution. We conducted a systematic review to synthesize available evidence regarding measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in HIV-infected adolescents and adults to provide the evidence base for recommendations on the need for measles vaccination.Methods: We conducted searches of 8 databases through 26 September 2017. Identified studies were screened independently by 2 reviewers.Results: The search identified 30 studies meeting inclusion criteria. Across studies, measles seroprevalence among HIV-infected adolescents and adults was high (median, 92%; 27 studies), with no significant difference compared to HIV-uninfected participants (10 studies). In 6 studies that evaluated the immunogenicity of MCVs among seronegative HIV-infected adults, measles seropositivity at end of follow-up ranged from 0% to 56% (median, 39%). No severe adverse events were reported following measles vaccination in HIV-infected patients.Conclusions: Based on similar measles seroprevalence between HIV-infected and HIV-uninfected adolescents and adults, and the low response to vaccination, these studies do not support the need for an additional dose of MCV in HIV-infected adolescents and adults. These findings support WHO guidelines that measles vaccine be administered to potentially susceptible, asymptomatic HIV-infected adults, and may be considered for those with symptomatic HIV infection if not severely immunosuppressed. Measles-susceptible adolescents and adults, regardless of HIV status, may require targeted vaccination efforts to reach critical vaccination thresholds and achieve regional elimination goals.Keywords
This publication has 33 references indexed in Scilit:
- Lessons and Challenges for Measles Control from Unexpected Large Outbreak, MalawiEmerging Infectious Diseases, 2013
- Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adultsVaccine, 2011
- Immunologic Basis for Revaccination of HIV-Infected Children Receiving HAARTFuture Virology, 2010
- Seroprevalence of common vaccine-preventable viral infections in HIV-positive adultsJournal of Infection, 2010
- Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation testsJournal of Clinical Virology, 2007
- Measles immunity testing: Comparison of two measles IgG ELISAs with plaque reduction neutralisation assayJournal of Virological Methods, 2006
- Measles seroprevalence and vaccine response in HIV-infected adultsVaccine, 1994
- Prevalence of measles antibodies in adults with HIV infectionAIDS, 1992
- Immunity to Measles and Rubella in Women Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1992
- Prevalence of Measles Antibodies in Asymptomatic Human Immunodeficiency Virus-Infected AdultsThe Journal of Infectious Diseases, 1991